特别提示：本公告所载2024年度的财务数据仅为初步核算数据，未经会计师事务所审计，与年度报告中 披露的最终数据可能存在差异，请投资者注意投资风险。 登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002741 证券简称：光华科技 公告编号：2025-013 广东光华科技股份有限公司 2024年度业绩快报 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导性陈述或重大遗 漏。 一、2024年度主要财务数据和指标 单位：万元 ■ 二、经营业绩和财务状况情况说明 （一）经营业绩、财务状况 2024 年度公司实现营业收入258,900.78万元，同比减少4.09%；归属于上市公司股东的净利润-20,494.72 万元，同比减亏52.42%，扣除非经常性损益后的归属于上市公司股东的净利润-16,407.21万元，同比减 亏62.04%。 （二）影响经营业绩的主要因素 受行业周期性波动影响，新能源材料订单需求不足，碳酸锂等产品价格持续低位，新能源材料板块获利 能力继续下降，导致经营亏损。另公司根据《企业会计准则》、《深圳证券交易所股票上市规则》、 《深圳证券交易所上市公司自律监管指南 ...

Group 1: Company Announcements - China Pacific Insurance (China Life) expects a net profit increase of 30% to 50% for Q1 2025, projecting a profit range of 11.652 billion to 13.445 billion yuan [2] - New Lai Fu plans to acquire 100% equity of Guangzhou Jin Nan Magnetic Materials, with trading suspension starting from April 14, 2025, due to significant asset restructuring [3] - Jiangling Motors intends to repurchase A-shares with a total fund of no less than 1.5 billion and no more than 2 billion yuan, at a price not exceeding 22.00 yuan per share [4] - Guanghua Technology anticipates a net profit increase of 479.25% to 637.23% for Q1 2025, estimating a profit range of 22 million to 28 million yuan [7] - Starhua New Materials reported a net profit of 148 million yuan for 2024, with a year-on-year increase of 51.93%, and plans to distribute a cash dividend of 8 yuan per 10 shares [10] Group 2: Clinical Trial Approvals - Heng Rui Pharmaceutical received approval for clinical trials of HRS-9190, a new drug for anesthesia, and SHR-3792, an innovative anti-tumor candidate, with no similar drugs approved in the market [1]

Group 1: Company Performance - Guanghua Technology expects a net profit growth of 479% to 637% year-on-year for Q1 2025, with an estimated profit of 22 million to 28 million yuan, driven by business expansion in specialized chemicals and cost reduction measures [1] - China Pacific Insurance anticipates a net profit increase of 30% to 50% year-on-year for Q1 2025, projecting a profit of 11.652 billion to 13.445 billion yuan, attributed to improved business quality and significant investment performance [2] - Zhenyu Technology forecasts a net profit growth of 31.54% to 42.97% year-on-year for Q1 2025, estimating a profit of 69 million to 75 million yuan, supported by increased sales orders and enhanced production automation [7] - Chuangjiang New Materials expects a net profit increase of 26.74% to 46.24% year-on-year for Q1 2025, with an estimated profit of 130 million to 150 million yuan, driven by stable growth in production and sales [8] Group 2: Corporate Actions - Xinlaifu plans to acquire 100% equity of Guangzhou Jinnan Magnetic Materials, leading to a significant asset restructuring, with trading suspended from April 14, 2025 [2] - Jiangling Motors intends to repurchase A-shares worth 150 million to 200 million yuan for employee stock ownership plans or equity incentives [5] - Yingfeite plans to repurchase shares worth 50 million to 100 million yuan for employee stock ownership or equity incentive plans [6] - Guanghua Technology's major shareholder is undergoing a change in its upper equity structure, but the actual controller remains the Zhuhai State-owned Assets Supervision and Administration Commission [4] Group 3: Regulatory Approvals - Hengrui Medicine received approval for clinical trials of its new drug HRS-9190, which is intended for use during anesthesia induction and maintenance [9]

4月13日晚间光华科技（002741）披露了2024年业绩快报及2025一季度业绩预告。 根据披露的调整方案，光华科技综合考量新能源材料生产原材料供应及能源成本等关键因素，为进一步 强化产业链上下游稳定协同合作关系，公司计划通过合理调整生产基地的布局，对产业链进行优化，有 效降低生产成本，提高公司新能源产品的综合竞争力。 同时，鉴于对新能源材料板块布局及生产计划调整，涉及部分设备设施将停止运行或出售，公司对该调 整涉及的各项长期资产进行了减值测试，根据测试结果及会计准则规定充分计提减值准备，真实反映资 产的公允价值。 该公司表示，本次调整是公司根据市场变化及实际经营发展需要做出的积极应对，契合公司未来业务拓 展需要，公司通过重新规划各项资产的使用方案，实现资产利用率的最大化，为公司持续健康发展提供 有力支撑。 2024年，光华科技实现营业收入25.89亿元，同比减少4.09%；归属净利润-2.05亿元，同比减亏52.42%， 扣非净利润-1.64亿元，同比减亏62.04%。 对于2024年业绩表现，光华科技表示，受行业周期性波动影响，新能源材料订单需求不足，碳酸锂等产 品价格持续低位，新能源材料板块获利能力继 ...

Core Viewpoint - Guanghua Technology (002741) expects a significant increase in net profit for Q1 2025, projecting a net profit attributable to shareholders of 22 million to 28 million yuan, representing an increase of 479.25% to 637.23% compared to the same period last year [1] Financial Performance - The expected net profit after deducting non-recurring gains and losses is projected to be between 17.95 million and 23.95 million yuan, which is an increase of 639.87% to 887.18% year-on-year [1] - The basic earnings per share are anticipated to be between 0.05 yuan and 0.06 yuan [1] Business Strategy - The company continues to strengthen its efforts in expanding the specialized chemical products segment, aiming to break through key benchmark customers in the industry [1] - There is a focus on cost reduction and efficiency improvement to enhance product competitiveness and operational efficiency [1]

[Key Financial Data and Indicators](index=1&type=section&id=Item%201.%20Key%20Financial%20Data%20and%20Indicators) The company's 2024 total operating revenue decreased by 4.09%, yet net loss attributable to shareholders significantly narrowed by 52.42%, with period-end total assets and equity showing growth Key Financial Data and Indicators | Item | Current Period | Prior Period | Change (%) | | :--- | :--- | :--- | :--- | | **Operating Performance** | | | | | Total Operating Revenue (million yuan) | 2,589.01 | 2,699.46 | -4.09 | | Operating Profit (million yuan) | -183.59 | -510.46 | 64.03 | | Total Profit (million yuan) | -201.34 | -516.20 | 61.00 | | Net Profit Attributable to Shareholders (million yuan) | -204.95 | -430.71 | 52.42 | | Net Profit Attributable to Shareholders (Excl. Non-recurring Items) (million yuan) | -164.07 | -432.22 | 62.04 | | Basic Earnings Per Share (yuan) | -0.51 | -1.08 | 52.78 | | **Financial Position (Period-End)** | **Current Period-End** | **Prior Period-End** | **Change (%)** | | Total Assets (million yuan) | 3,511.24 | 3,242.06 | 8.30 | | Owners' Equity Attributable to Shareholders (million yuan) | 1,832.39 | 1,347.43 | 35.99 | | Share Capital (million yuan) | 465.02 | 399.48 | 16.41 | | Net Assets Per Share Attributable to Shareholders (yuan) | 3.94 | 3.37 | 16.91 | [Explanation of Operating Performance and Financial Position](index=1&type=section&id=Item%202.%20Explanation%20of%20Operating%20Performance%20and%20Financial%20Position) The company's 2024 loss is primarily due to the new energy materials segment's reduced profitability from market downturns and low product prices, compounded by significant asset impairment and disposal losses - In 2024, the company achieved total operating revenue of **2.589 billion yuan**, a **4.09%** year-on-year decrease; net profit attributable to shareholders was **-205 million yuan**, representing a **52.42%** reduction in loss year-on-year[5](index=5&type=chunk)[6](index=6&type=chunk) - The primary reason for the performance loss is the new energy materials segment's reduced profitability due to industry cyclical fluctuations, insufficient order demand, and persistently low prices for products like lithium carbonate[7](index=7&type=chunk) - The company recognized approximately **140 million yuan** in impairment provisions for long-term assets related to the new energy materials segment and approximately **24.2 million yuan** in long-term asset disposal losses, negatively impacting current period profit[7](index=7&type=chunk) [Explanation of Differences from Previous Performance Forecast](index=2&type=section&id=Item%203.%20Explanation%20of%20Differences%20from%20Previous%20Performance%20Forecast) The net profit data in this performance express report shows no significant difference from the previous forecast, with only a reclassification of asset impairment during audit not impacting key financial totals - Preliminary calculations indicate no significant difference between the 2024 net profit attributable to shareholders and the previously disclosed performance forecast data[8](index=8&type=chunk) - During the annual audit, following communication with the accounting firm, the company reclassified asset impairment items originally recorded as non-recurring gains/losses to recurring gains/losses, an adjustment that does not affect total revenue, total profit, or total assets[8](index=8&type=chunk) [Other Explanations and Reference Documents](index=2&type=section&id=Item%204.%20Other%20Explanations) This performance express report contains preliminary, unaudited financial results, with final data subject to the audited 2024 annual report, and investors should be aware of investment risks - This performance express report represents preliminary calculations by the company's finance department, with final financial data subject to the audited 2024 annual report, and investors are reminded to be aware of investment risks[9](index=9&type=chunk) - Reference documents include comparative balance sheets and income statements signed and sealed by the company's legal representative, chief financial officer, and head of accounting[10](index=10&type=chunk)

Financial Performance - The estimated net profit attributable to shareholders for Q1 2025 is projected to be between 22 million and 28 million CNY, representing an increase of 479.25% to 637.23% compared to the same period last year, which was 3.798 million CNY [2]. - The estimated net profit after deducting non-recurring gains and losses is expected to be between 17.95 million and 23.95 million CNY, reflecting an increase of 639.87% to 887.18% year-over-year, compared to 2.4261 million CNY last year [2]. - The basic earnings per share is projected to be between 0.05 CNY and 0.06 CNY, up from 0.01 CNY in the same period last year [2]. - The financial data provided in the earnings forecast is preliminary and has not been audited by an external accounting firm, with final figures to be disclosed in the Q1 2025 report [5]. Operational Strategy - The company has intensified its efforts in the specialized chemical products sector, successfully breaking into key benchmark clients and further expanding its leading position in this field [4]. - Continuous cost reduction and efficiency enhancement measures have been implemented to improve product competitiveness and overall operational efficiency [4].

一、募集资金基本情况 根据中国证券监督管理委员会《关于同意广东光华科技股份有限公司向特定对象发行 股票注册的批复》（证监许可〔2023〕2502号），公司向特定对象发行人民币普通股（A股） 65,543,067股，发行价格为人民币10.68元/股，募集资金总额为人民币699,999,955.56元，扣 除保荐承销费用、律师费用、审计验资费及发行手续费共11,116,172.14元（不含税）后，募 集资金净额为人民币688,883,783.42元。众华会计师事务所（特殊普通合伙）已就公司本次 向特定对象发行股票募集资金的到位情况出具了《验资报告》（众会字[2024]第10629号）。 募集资金到账后，公司已对募集资金进行了专户存储管理，公司与保荐机构、存放募集资 金的商业银行签订了《募集资金专户存储三方监管协议》。 二、募集资金使用情况 东方证券股份有限公司 关于广东光华科技股份有限公司 变更部分募集资金投资项目的核查意见 东方证券股份有限公司（以下简称"保荐机构"）作为广东光华科技股份有限公司 （以下简称"光华科技"或"公司"）向特定对象发行股票并上市的保荐机构，根据《证 券发行上市保荐业务管理办法》《上市公 ...

证券代码：002741 证券简称：光华科技 公告编号：2025-013 广东光华科技股份有限公司 关于计提信用及资产减值准备的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，不存在虚假记 载、误导性陈述或重大遗漏。 一、本次计提减值准备情况概述 （一）计提减值准备的原因 当单项应收票据及应收账款无法以合理成本评估预期信用损失 的信息时，本公司依据信用风险特征将应收票据及应收账款划分为若 干组合，在组合基础上计算预期信用损失。如果有客观证据表明某项 应收票据及应收账款已经发生信用减值，则本公司对该应收票据及应 收账款单项计提坏准备并确认预期信用损失。对于划分为组合的应收 票据及应收账款，本公司参考历史信用损失经验，结合当前状况以及 对未来经济状况的预测，通过违约风险敞口和整个存续期预期信用损 失率，计算预期信用损失。 根据《企业会计准则》《深圳证券交易所股票上市规则》《深圳 证券交易所上市公司自律监管指南第1号——业务办理》等有关规定， 为真实、准确反映公司财务状况、资产价值及经营成果，基于谨慎性 原则，公司对截至2024年12月31日的各类资产进行清查，对存在减值 迹象的相关资产计提相应的减值准备。 ...

一、综合考量公司新能源材料生产原材料供应及能源成本等关键因素，为进 一步强化产业链上下游稳定协同合作关系，公司计划通过合理调整生产基地的布 局，对产业链进行优化，有效降低生产成本，提高公司新能源产品的综合竞争力。 二、鉴于对新能源材料板块布局及生产计划调整，涉及到部分设备设施将停 止运行或出售，公司对该调整涉及的各项长期资产进行了减值测试，根据测试结 果及会计准则规定充分计提减值准备，真实反映资产的公允价值。截至 2024 年 12 月 31 日止，公司对相关长期资产计提了减值准备约 13,970 万元，确认的长 期资产处置损失约 2,420 万元。上述金额未经审计，届时将以审计确认的结果为 准。 三、本次优化调整对公司的影响 广东光华科技股份有限公司 关于优化新能源产业布局的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，不存在虚假记 载、误导性陈述或重大遗漏。 受新能源材料行业周期性波动影响，碳酸锂等产品价格持续维持在低位，基 于当前宏观经济形势、锂电池材料行业现状，为了更好提升公司新能源产品在市 场的综合竞争力，公司拟对新能源业务板块战略布局做出优化调整，积极应对新 能源材料行业周期性波动对公 ...